REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Conference Call Information
When: Monday, November 6, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI0eececfba52f4f83a7438c9f002fabc4
Webcast: https://edge.media-server.com/mmc/p/z2fatkzx
A press release containing the third quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call. Please also review our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which will be available at https://investors.coherus.com and available via EDGAR on the SEC’s website at www.sec.gov on November 6, 2023 for more information about our third quarter financial results.
A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.
Coherus Contact Information:
Jodi Sievers
VP, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.04 |
Daily Change: | 0.11 5.70 |
Daily Volume: | 901,403 |
Market Cap: | US$231.540M |
April 24, 2024 April 08, 2024 March 13, 2024 March 05, 2024 February 21, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORESurmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB